Therapies targeting VEGF family proteins have had success in several cancer types: bevacizumab in colorectal [1], lung [2], brain [3], and kidney [4]; aflibercept in colorectal [5]; sorafenib in kidney and liver; sunitinib in gastrointestinal stromal, kidney, and pancreatic neuroendocrine; pazopanib for kidney and soft tissue sarcoma (www.cancer.gov). Here, VEGFA is linked to cancer.